USANew treatments and approvals
Revakinagene taroretcel, an implanted cell therapy for MacTel type 2, approved
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The FDA has approved revakinagene taroretcel for macular telangiectasia type 2. This disease causes progressive vision loss in the retina. In the treatment, a small implant is surgically placed in the eye. Cells inside the implant continuously release a protective protein (CNTF) to the retina. Two phase 3 studies reported slower loss of light-sensing cells over 24 months.
What does it mean for patients and families?
This is the first treatment approved for this disease. It aims to slow progression rather than restore lost vision. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
AJMC: FDA Approves Revakinagene Taroretcel for Macular Telangiectasia Type 2
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Macular telangiectasia type 2 (MacTel)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.